LOGIN  |  REGISTER
Terns Pharmaceuticals
Amneal Pharmaceuticals

Guardant Health to Participate in Upcoming Investor Conferences

February 10, 2025 | Last Trade: US$61.40 0.12 0.20

PALO ALTO, Calif. / Feb 10, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.

  • BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT
    Hosting 1x1 meetings on Tuesday, February 11th and Wednesday, February 12th
  • TD Cowen 45th Annual Health Care Conference in Boston, MA
    Fireside chat on Tuesday, March 4th at 10:30 a.m. Eastern Time
  • Leerink Partners Global Health Conference in Miami, FL
    Fireside chat on Tuesday, March 11th at 4:20 p.m. Eastern Time
  • Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL
    Fireside chat on Wednesday, March 12th at 1:30 p.m. Eastern Time

Interested parties may access live and archived webcasts of the sessions on the “Investors” section of the company website at: www.guardanthealth.com.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

 

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page